2026 Publications

Title

Author

Journal

Date

Link

Non-viral vectors as beacons of hope for reducing genotoxic risks of gene therapy.

Nzila MM et al.

Nat Biomed Eng.

5 January 2026

Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.

Ianevski A et al.

Cancer Res.

16 January 2026

Delineating phenotypic heterogeneity in human regulatory T cells across developmental stages and therapeutic sources

Samikshya Santosh Nirmala et al.

Frontiers Immunology

22 January 2026

Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation - PubMed

Kristina Roth et al.

Blood

26 January 2026

Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe.

Ammar D et al.

Cytotherapy

28 January 2026

Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.

Rieger L et al.

Blood

29 January 2026

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.

Riester Z et al.

Mol Ther.

4 February 2026

From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapies.

Tietze M et al.

iScience.

5 February 2026

The ticking clock of relapse in T-cell lymphomas.

Jiang Q et al.

Blood.

12 February 2026

MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.

Wiemers TC et al.

Leukemia

17 February 2026

Artificial intelligence-generated synthetic data for cancer research and clinical trials.

Eckardt JN et al.

Nat Rev Cancer.

20 February 2026

Extracorporeal photopheresis-New insights into an old procedure.

Seiffert S et al.

Transfus Med.

February 2026

The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation.

Franke GN et al.

Bone Marrow Transplant.

February 2026

Epigenetic editing balances TCR suppression and persistence in CAR T cells.

Schönberg PY, Muñoz-Ovalle Á, Saleh HA, Crespo E, Kuhnert R, Michen S, Loureiro L, Temme A, Feldmann A, Buchholz F.

Mol Ther Adv.

6 March 2026

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.

Rade M, Fandrei D, Kreuz M, Seiffert S, Grahnert A, Friedrich M, Wiemers T, Born P, Fischer L, Weidner H, Hofbauer LC, Baber R, Wang SY, Bach E, Hoffmann S, Scolnick J, Friedrich M, Keramati F, Brazda P, Sebestyen Z, Kuball J, Alb M, Scheller L, Hudecek M, Einsele H, Metzeler KH, Herling M, Herling CD, Jentzsch M, Franke GN, Boldt A, Köhl U, Platzbecker U, Vucinic V, Reiche K, Merz M.

Cancer Cell.

9 March 2026

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Höllein A, Kraus S, Schäfer-Eckart K, Hänel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Röhnert MA, Oelschlägel U, Wagenführ L, Thiede C, Herold S, Poitz D, Stölzel F, Baldus CD, Serve H, Wermke M, Bornhäuser M, Röllig C.

Lancet Haematol.

13 March 2026

Epigenetic editing balances TCR suppression and persistence in CAR T cells.

Schönberg PY, Muñoz-Ovalle Á, Saleh HA, Crespo E, Kuhnert R, Michen S, Loureiro L, Temme A, Feldmann A, Buchholz F.

Mol Ther Adv.

March 2026

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Florey C, Velazquez GF, Lesan V, Krämer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Gödel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hänel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Müller F, Lenz G.

Haematologica.

2 April 2026

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma.

Schlierkamp-Voosen T, Barden M, Janning H, Kaljanac M, Harrer DC, Dreger C, Hammon K, Ertelt M, Schoeder CT, Halldórsdóttir HR, Rodriguez-Pardo C, Hadrup SR, Thomas S, Abken H.

Front Immunol.

30 April 2026

CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.

Keitel V, Kreissl MC, Goetze T, Dröge C, Kuhn CK, Pham NN, Löffler D, Borie D, Schreiber J, Boettcher M, Hippe K, Pech M, Mikusko M, Köhl U, Walther D, Reiche K, Mougiakakos D.

J Hepatol.

April 2026

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.

Velasco-de-Andrés M, Puerta-Alcalde P, Eitler J, Krutz L, Chumbita M, Español-Rego M, Català C, Carrillo-Serradell L, Planells-Romeo V, Aragón-Serrano L, Vergara A, Pérez-Valencia AI, Monzó-Gallo P, Gallardo-Pizarro A, Cibeira MT, Vlagea A, Caro JL, Palou E, Suárez-Lledó M, Soriano A, Calvo G, Urbano-Ispizua Á, Tonn T, Garcia-Vidal C, Lozano F.

Front Immunol.

8 May 2026

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.

Ferle M, Ader J, Wiemers T, Grieb N, Berneck B, Lindenmeyer A, Goldschmidt H, Mai EK, Bertsch U, Meyer HJ, Neumuth T, Kreuz M, Reiche K, Merz M.

NPJ Digit Med.

11 May 2026

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.

Rasche L, Krauth MT, Agis H, Renner C, Strassl I, Teipel R, Vučinić V, Weisel K, Willenbacher W, Raab MS.

Bone Marrow Transplant.

13 May 2026

INSTALLing recombinase-driven genome writing: Engineered single-stranded donors bypass innate immunity to enable large DNA integration.

Buchholz F.

Mol Cell.

21 May 2026

Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Teipel R, Trautmann-Grill K, Kleditsch L, Epp K, Böttcher S, Röllig C, Weidner H, Gottschalk A, Glauche I, Brogsitter C, Platzek I, Apolle R, Bonin MV, Bornhäuser M, Winzer R, Miederer M.

Haematologica.

21 May 2026

Developing a pan cancer therapy based on DISE-inducing short RNAs.

Murmann AE, Ebadi M, Patel M, Ewe A, Barajas S, Xiao S, Ko MJ, Lee S, Cai W, Paudel B, Sun L, Bartom ET, Kocherginsky M, Liu Y, Kim DH, Aigner A, Peter ME.

Mol Ther Nucleic Acids.

25 May 2026

Artificial intelligence-generated synthetic data for cancer research and clinical trials.

Eckardt JN, Hahn W, Prelaj A, Bornhäuser M, Middeke JM, Kather JN.

Nat Rev Cancer.

26 May 2026

Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

Krauß SM, Holloway T, Weigert A, Bischof L, Backhaus D, Brauer D, Ussmann J, Franke GN, Vučinić V, Platzbecker U, Schwind S, Jentzsch M, Metzeler KH.

Haematologica

28 May 2026

JUN Specifies the Local Differentiation and Maintenance of Pro-tumoral Monocyte-Derived Macrophages.

Delfini M, Baudoin E, Guo G, Francois M, Bebien M, Murgaski A, Bettacchioli E, Buferne M, Rastoin O, Belabed D, Moussard P, Mariot C, Baranska A, Verthuy C, Ruffinatto L, Mossadegh-Keller N, Vu Manh TP, Masse M, Soni A, Sieweke MH, Strauss LM, Pauladóttir Jensen M, Doktor TK, Etzerodt A, Auphan-Anezin N, Lawrence T.

Cancer Res.

29 May 2026

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Waldschmidt J, Fandrei D, Hecker JS, Meggendorfer M, Truger M, Reinhard F, Shibru B, Högner M, Gebauer A, Köppel M, Müller H, Jung J, Teschner D, Topp MS, Purcarea A, Vučinić V, Haferlach T, Bassermann F, Platzbecker U, Einsele H, Haferlach C, Kortüm KM, Metzeler KH, Merz M, Götze KS, Rasche L.

Leukemia.

May 2026

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.

Krauß SM, Weibl K, Bach E, Brückner M, Weigert A, Tumewu T, Ruschpler E, Vogtmann G, Hoffmann S, Penack O, Janz M, Buhmann R, Henschler R, Bullinger L, Keller U, Schwind S, Merz M, Jentzsch M, Franke GN, Herling M, Platzbecker U, Metzeler KH, Vučinić V.

Bone Marrow Transplant.

3 June 2026

Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.

Hübner J, Alsalkini M, McFleder R, Toppeta F, Wagner J, Liguori R, Grams B, Meyer-Hofmann M, Diener L, Monoranu CM, Hagemann C, Ferrazzi F, Ip CW, Ernestus RI, Einsele H, Hudecek M, Löhr M, Nerreter T, Nickl V.

J Immunother Cancer.

3 June 2026

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Merz M, Jelinek T, Pabst T, Teipel R, Albici AM, von Tresckow B, Teichert M, Demel UM, Busse A, Wesener MC, Holderried TAW, Schmitz F, Rößiger FL, Müller F, Hoffmann M, Stölzel F, Tovar N, Baermann BN, Stork M, Jungova A, Minarik J, Radocha J, Spicka I, Pour L, Novak P, Slajpah K, Rener K, Keller U, Bohl S, Fandrei D, Born P, Vucinic V, Kröger N, Strassl I, Schub N, Hájek R, Sever M, Fernández de Larrea C, Gagelmann N.

Blood Cancer Discov.

12 June 2026

Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications.

Schadt J, von Bonin M, Oelschlägel U, Teipel R, Epp K, Saalfeld FC, Schulze F, Heuschkel S, Bornhäuser M, Röhnert MA.

Leukemia

27 June 2026

Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies

Ruppel KE, Lückemeier P, Scholz A, Stahringer A, Reiche K, Köhl U, Fricke S, Herling M, Schmiedel D

Cytotherapy

28 July 2026

Precision Therapy Cluster

More Information